Ancora Advisors LLC Makes New $830,000 Investment in Thermo Fisher Scientific Inc. $TMO

Key Points

• Ancora Advisors initiated a $830,000 position in Thermo Fisher Scientific during the second quarter, purchasing 1,655 shares. Institutional investors collectively own 89.23% of the company.
• Thermo Fisher reported strong quarterly results, with adjusted EPS of $6.03 and revenue of $11.99 billion, up 10.5% year over year. Fiscal 2026 EPS guidance remains $24.93–$25.33, though the stock’s valuation is elevated at roughly 33.9 times earnings.
• Analysts maintain a favorable “Moderate Buy” consensus, but the average $619.41 price target is below the recent share price of $630.66. Insiders have sold $44.1 million of stock over the past quarter, primarily through pre-arranged Rule 10b5-1 plans.

Ancora Advisors LLC purchased a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 1,655 shares of the medical research company's stock, valued at approximately $830,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. J. Stern & Co. LLP boosted its position in shares of Thermo Fisher Scientific by 58,006.4% during the 4th quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company's stock worth $18,258,082,000 after purchasing an additional 31,455,105 shares during the period. BlackRock Inc. acquired a new position in Thermo Fisher Scientific during the second quarter worth $15,501,867,000. State Street Corp boosted its position in shares of Thermo Fisher Scientific by 1.4% during the fourth quarter. State Street Corp now owns 16,613,761 shares of the medical research company's stock worth $9,633,991,000 after buying an additional 229,630 shares during the period. Capital World Investors grew its stake in shares of Thermo Fisher Scientific by 7.0% in the fourth quarter. Capital World Investors now owns 11,003,814 shares of the medical research company's stock valued at $6,376,229,000 after buying an additional 718,669 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Thermo Fisher Scientific by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 8,196,477 shares of the medical research company's stock valued at $4,728,129,000 after buying an additional 26,425 shares during the period. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific News Roundup

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Thermo Fisher introduced the Thermo Scientific EMPAD G2 electron detector, designed to enable faster, high-speed four-dimensional scanning transmission electron microscopy. The product could support demand for the company’s analytical-instrument portfolio and strengthen its position in advanced materials research. Thermo Fisher Scientific Introduces the EMPAD G2 Electron Detector
• Positive Sentiment: A recent analysis examines whether Isora could provide Thermo Fisher with an additional long-term growth opportunity, potentially broadening the company’s exposure to emerging research and laboratory markets. Can Isora Unlock a New Growth Edge?
• Neutral Sentiment: Thermo Fisher’s latest reported quarter showed solid momentum: adjusted EPS of $6.03 exceeded estimates, revenue reached $11.99 billion, and sales increased 10.5% year over year. Fiscal 2026 EPS guidance remains $24.93-$25.33, but much of this strength may already be reflected in the stock’s elevated valuation.
• Neutral Sentiment: Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating, although the average price target of $619.41 is below recent trading levels. Several firms have raised targets toward $650, suggesting optimism but limited upside at the current valuation.
• Negative Sentiment: CEO Marc Casper sold 275 shares for approximately $172,000 after selling 10,000 shares worth about $6.3 million earlier in the month. Both transactions were executed under pre-arranged Rule 10b5-1 plans, reducing their significance as a signal of deteriorating fundamentals, but the sales can still weigh on sentiment.

Insiders Place Their Bets

In related news, COO Gianluca Pettiti sold 400 shares of the company's stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $565.00, for a total value of $226,000.00. Following the completion of the transaction, the chief operating officer directly owned 24,651 shares of the company's stock, valued at $13,927,815. This represents a 1.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael D. Shafer sold 25,500 shares of the firm's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the sale, the executive vice president directly owned 20,994 shares in the company, valued at approximately $12,596,400. The trade was a 54.85% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 73,768 shares of company stock worth $44,122,820. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Stock Down 0.5%

Shares of Thermo Fisher Scientific stock opened at $630.66 on Friday. Thermo Fisher Scientific Inc. has a 52-week low of $435.27 and a 52-week high of $647.00. The company has a 50 day moving average of $555.52 and a 200 day moving average of $511.31. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The company has a market capitalization of $233.18 billion, a P/E ratio of 33.92, a P/E/G ratio of 2.58 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating analysts' consensus estimates of $5.71 by $0.32. The business had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company's revenue was up 10.5% on a year-over-year basis. During the same period last year, the business earned $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, research analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific's payout ratio is 10.11%.

Analyst Ratings Changes

TMO has been the subject of several research reports. Wall Street Zen raised Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Saturday, August 1st. Evercore set a $570.00 price objective on shares of Thermo Fisher Scientific in a research note on Monday, July 6th. Wolfe Research began coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They set an "outperform" rating and a $535.00 target price on the stock. KeyCorp reiterated an "overweight" rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. Finally, Jefferies Financial Group restated a "buy" rating and issued a $630.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, July 23rd. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $619.41.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source